News

News Subscription

May 31. 2021
Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer
Read more
Download
May 19. 2021
Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic
Read more
Download
Apr 21. 2021
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 01. 2021
Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary
Read more
Download
Mar 24. 2021
Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Read more
Download
Feb 24. 2021
Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million
Read more Download
Feb 23. 2021
Basilea launches a private placement of new shares by way of an accelerated bookbuilding
Read more Download
Feb 16. 2021
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Read more
Download
Feb 15. 2021
Basilea announces divestment of its Chinese R&D subsidiary to PHT International
Read more
Download
Feb 12. 2021
Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium
Read more
Download